REG - Adv Medical Solutns. - Director- PDMR Dealing Announcement

Advanced Medical SolutionsAnnouncement

13/05/2022 18:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220513:nRSM5200La&default-theme=true

RNS Number : 5200L  Advanced Medical Solutions Grp PLC  13 May 2022

     13 May 2022

            Advanced Medical Solutions Group plc

("AMS", the "Company" or the "Group")

 

            Director/PDMR Shareholding

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the
world-leading specialist in tissue-healing technologies, announces the
following PDMR share transactions.

 

The Company was notified on 10 May 2022 that following his decision to
participate in the Deferred Share Bonus (DSB), Chris Meredith, who is a
Director and PDMR, undertook the following transactions:

·    The exercise of 395,355 options from the Long-Term Incentive Plan
(LTIP).

·    The exercise of 34,608 options from the existing Deferred Annual
Bonus Plan (DAB).

·    Elected to receive an additional 543 dividend shares which were
earned during the holding period under the terms of the DAB.

·    The exercise of 23,415 Ordinary Shares of 5p from the existing DSB
and the award of 56,785 shares under the DSB.

·    The sale of 246,384 Ordinary Shares of 5p each on 10 May 2022 at a
share price of 271.5p per Ordinary Share by way of an off-market sale. The
proceeds from the sale of the shares was used to purchase shares in the DSB
and cover the tax payable on the above exercises.

 

The Trust which manages the Deferred Share Bonus Plan ("DSB") on behalf of the
employees of AMS purchased ordinary shares of 5 pence each ("Ordinary Shares")
between 10 and 12 May 2022, at an average price of 270.5p on behalf of Chris
Meredith as part of the DSB and, under the terms of the DSB, these shares will
be held in trust on his behalf.

 

As a result of these transactions Chris Meredith's beneficial interest in the
Company increased and his overall holding is as follows:

 

 PDMR            No. of DSBs after exercise  No. of DABs after exercise  No. of LTIPs after exercise  Resultant holding of Ordinary Shares  % of issued share capital
 Chris Meredith  117,709                     6,219                       877,145                      1,760,162                             0.82%

 

The Company was also notified on 12 May 2022 that following the decision by
Eddie Johnson, who is a Director and PDMR, to participate in the DSB the Trust
which manages the Deferred Share Bonus Plan ("DSB") on behalf of the employees
of AMS purchased ordinary shares of 5 pence each ("Ordinary Shares")  between
10 and 12 May 2022, at an average price of 270.5p on behalf of Eddie Johnson
as part of the DSB and, under the terms of the DSB, these shares will be held
in trust on his behalf. Eddie Johnson was awarded of 17,225 shares under the
DSB.

 

As a result of these transactions Eddie Johnson's beneficial interest in the
Company increased and his overall holding is as follows:

 

 

 PDMR           No. of DSBs after exercise  No. of DABs held  No. of LTIPs held  Resultant holding of Ordinary Shares  % of issued share capital
 Eddie Johnson  110,140                     12,737            348,258            84,309                                0.04%

 

The notification below, made in accordance with the requirements of the EU
Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them

 

 1.  Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name: Chris Meredith
 2.  Reason for the notification
 a)  Position/status: Director/PDMR
 b)  Initial notification/Amendment: Initial Notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name:   Advanced Medical Solutions Group plc
 b)  LEI: 213800HJP6OWOSZI1L74
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument: Ordinary Shares
     of 5p

     Identification code: GB0004536594
 b)  Nature of the transactions:

     ·        Exercise of 23,415 shares from the Deferred Share Bonus Plan

     ·        Exercise of 34,608 shares from the Deferred Annual Bonus Plan

     ·        Award of 543 Dividend Shares from the Deferred Annual Bonus
     Plan

     ·        Exercise of 395,355 shares from the Long-Term Incentive Plan

     ·        Sale of 246,384 shares

     ·        Purchase of 28,725 shares through the Deferred Share Bonus
     Plan

     ·        Award of 56,785 shares in the Deferred Share Bonus Plan
 c)  Price(s) and volume(s):

     Sale of shares:

Price(s)  Volume(s)
     £2.715    246,384
 d)  Aggregated information: (Relates to those shares sold only)

     Aggregated volume: 246,384

     Aggregated price: £2.715
 e)  Date of the transaction: 10/05/2022
 f)  Place of the transaction: London Stock Exchange, AIM Market (XLON)

d)

Aggregated information: (Relates to those shares sold only)

Aggregated volume: 246,384

Aggregated price: £2.715

e)

Date of the transaction: 10/05/2022

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

 

 

 1.  Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name: Eddie Johnson
 2.  Reason for the notification
 a)  Position/status: Director/PDMR
 b)  Initial notification/Amendment: Initial Notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name:   Advanced Medical Solutions Group plc
 b)  LEI: 213800HJP6OWOSZI1L74
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument: Ordinary Shares
     of 5p

     Identification code: GB0004536594
 b)  Nature of the transaction:

     ·        Purchase of 8,945 shares through the Deferred Share Bonus
     Plan

     ·        Award of 17,225 shares in the Deferred Share Bonus Plan
 c)  Price(s) and volume(s):

     Sale of shares: Nil
 d)  Aggregated information: (Relates to those shares sold only)

     Aggregated volume:

     Aggregated price:
 e)  Date of the transaction: 10/05/2022
 f)  Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

-End -

 

 

For further information, please visit www.admedsol.com
(http://www.admedsol.com) or contact:

 Advanced Medical Solutions Group plc             Tel: +44 (0) 1606 545508
 Chris Meredith, Chief Executive Officer

 Eddie Johnson, Chief Financial Officer

 Consilium Strategic Communications               Tel: +44 (0) 20 3709 5700
 Mary-Jane Elliott / Matthew Neal / Matthew Cole  AMS@consilium-comms.com

 Investec Bank PLC (NOMAD & Broker)               Tel: +44 (0) 20 7597 5970
 Daniel Adams / Gary Clarence

 HSBC Bank PLC (Broker)                           Tel: 44 (0) 20 7991 8888
 Sam McLennan / Joe Weaving / Stephanie Cornish

 

About Advanced Medical Solutions Group plc - see www.admedsol.com
(http://www.admedsol.com)

AMS is a world-leading independent developer and manufacturer of innovative
tissue-healing technology, focused on quality outcomes for patients and value
for payers. AMS has a wide range of surgical products including tissue
adhesives, sutures, haemostats, internal fixation devices and internal
sealants, which it markets under its brands LiquiBand(®), RESORBA(®),
LiquiBandFix8(®) and Seal-G(®). AMS also supplies wound care dressings such
as silver alginates, alginates and foams through its ActivHeal(®) brand as
well as under white label. Since 2019, the Group has made three acquisitions:
Sealantis, an Israeli medical device company with a patent-protected sealant
technology platform; Biomatlante, an established French developer and
manufacturer of innovative surgical biomaterial technologies and Raleigh, a UK
leading coater and converter of materials predominately for woundcare and
bio-diagnostics products.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the
Czech Republic and Israel, are sold globally via a network of multinational or
regional partners and distributors, as well as via AMS's own direct sales
forces in the UK, Germany, the Czech Republic and Russia. The Group has
R&D innovation hubs in the UK, Germany, France and Israel. Established in
1991, the Group has more than 700 employees. For more information, please
see www.admedsol.com (http://www.admedsol.com) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHDXLFFLELBBBQ